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Dear Sir,
In a paper by Waters and Licht published recently in Pediatric
Nephrology, eculizumab is presented as the emerging drug to
replace plasma exchange (PE) to treat and prevent atypical
hemolytic uremic syndrome (aHUS) [1], allowing complica-
tions possibly associated with chronic PE use related to
arteriovenous fistula and infusion of blood products (viral
infections, allergic reaction) to be avoided. Eculizumab is an
anti-C5 monoclonal humanized mouse antibody that binds to
C5 and prevents the action of C5 convertase that splits C5 in
C5a and C5b, impeding formation of the C5b-9 membrane-
attack complex (or MAC) that binds to and permeabilizes
cell membranes, thereby killing microorganisms but also
damaging host endothelial cells, as in aHUS. Eculizumab
treatment has been shown to be successful in several
reported aHUS cases. However, the use of this drug over
the long term is limited by extremely high cost, possible
infectious complications by Neisseria, and by fetal morbidity
in case of administration during pregnancy. Although it has
not yet been demonstrated, the possibility of developing
antieculizumab antibodies cannot be excluded.
Another recently proposed alternative to PE consists of
combined kidney–liver transplantation, which remains,
however, a high-risk procedure [1]. Because of the
limitations of the latter techniques and the necessity of
life-long treatment in a large number of cases, it seems
important to us to emphasize the possibility that an
adequate PE strategy could obtain long-term preservation
of renal function in aHUS. In aHUS, CFH mutations are the
most frequent. The prognosis in this group is poor, with
most patients developing end-stage renal failure (ESRF)
and a recurrence rate posttransplant of 80% [1] that, when
not adequately treated, lead to graft loss in 100% of cases.
Since our reports on successful aHUS treatment by
intensive daily PE on native kidney and on kidney
transplantation, followed by prophylactic PE pursued
indefinitely and intensified during relapses [2, 3], this
strategy has been widely recommended [4].
In this letter, we present theevolutionof three sisters,two of
whomarehomozygote twinspresentingwithaHUSassociated
with CFH mutation (c.3572 C>T, Ser1191Leu) since data
published in our previous paper [3]. These observations
represent the longest successful prophylactic PE treatment
used in aHUS. The oldest sister is more than 20 years old and
received her third kidney transplant at the age of 17 under
prophylactic PE initiated from before transplantation. Four
months later, she experienced a severe relapse when the
frequency of PE was reduced from two to one sessions per
week. Immediate treatment by daily PE resulted in complete
recovery of baseline renal function. Later on, due to severe
reaction to plasma, PE had to be replaced with eculizumab
treatment, which prevented HUS relapse and renal function
deterioration (plasma creatinine 125 μmol/L 2 years after
eculizumab initiation). Twin 1 [2, 3] presented an initial HUS
episode at the age of 5 years. She reached ESRF 6 months
later despite having received ten daily PE sessions initially
and three courses of plasma infusion at the time of
hematological exacerbation of the disease. She was trans-
planted with a cadaver kidney 2 years later under prophylac-
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DOI 10.1007/s00467-011-1925-7tic PE (40 ml/kg of fresh frozen plasma) just before
transplantation and then daily for 7 days, being progressively
tapered and continued indefinitely once a week until now.
Eight years posttransplantation, plasma creatinine was
145 μmol/L despite two relapses in the early posttransplanta-
tion period secondary to cytomegalovirus (CMV) infection,
which responded well to daily PE sessions and ganciclovir.
Twin 2 presented a first episode of HUS 6 months after her
twin sister [3]. She was immediately treated with daily PE for
21 days until normalization of plasma creatinine and
thereafter tapered to one session/2 weeks until now. Ten
years after the first episode, plasma creatinine was normal
(57 μmol/L), and the patient did not present any urinary
abnormality. Long-term regular PE sessions did not worsen
school performance and social life in that family.
All three patients presented reactions to plasma that
indicated in each case the use of Octaplas instead of fresh
frozen plasma. Octaplas is a plasma preparation that
considerably reduces reaction risk by assuming complete
removal of cells and cell debris by multiple size-exclusion
filtration steps. The latter product is also submitted to virus
inactivation by S/D methods.
In conclusion, in this family ofpatients with aHUS related to
CFH mutation, intensive and prophylactic treatment with PE
allowed long-term preservation of transplant and native renal
function. However, because of the burden of this technique,
the cost of eculizumab, and the high risk of liver transplan-
tation, the best option for treating aHUS related to CFH
mutation might be a human-plasma-derived CFH concentrate,
presently being developed in France by the Laboratoire
Francais du Fractionnement et des Biotechnologies.
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